Civica Rx

Visory Health Names Highly Decorated Army Colonel to Serve as Chief Clinical Officer

Retrieved on: 
Thursday, November 9, 2023
Health, Defense, Other Health, Health Insurance, General Health, Veterans, Risk, Operation Provide Promise, RAND, CSH, United States Army Human Resources Command, Veterans Health Administration, United Nations Protection Force, Medical-surgical nursing, AAS, Principal investigator, Courage, Order of Military Medical Merit, United Nations, Combat support hospital, Operation, Empowerment, 67th Combat Support Hospital (United States), Research, University, Capital region, Caregiver, Prescription, ID, Visori, War, Defense Health Agency, Woman, Army, Civica Rx, Harvard University, Consultant, Health insurance, Nursing, Veteran

Visory Health , a simple, patient-first platform that provides lower prices on prescriptions, announces the appointment of highly decorated Army Colonel Dr. Cheryl Creamer as the company’s Chief Clinical Officer.

Key Points: 
  • Visory Health , a simple, patient-first platform that provides lower prices on prescriptions, announces the appointment of highly decorated Army Colonel Dr. Cheryl Creamer as the company’s Chief Clinical Officer.
  • Veterans often face significant challenges when it comes to accessing healthcare, particularly in terms of mental health support and prescription medications.
  • According to RAND research , only about half of all veterans who need mental health care ever receive it due to a series of roadblocks.
  • Dr. Creamer brings unmatched expertise, leadership and compassion to Visory Health, positioned as a liaison between Veterans and affordable medications.

Martin Van Trieste Appointed Chair of the Board for SmartSkin Technologies

Retrieved on: 
Thursday, September 14, 2023
Pond, Amgen, Partnership, Culture, Civica Rx, Risk management, Thought, Growth, Cryptocurrency, Renewable energy, Management, NB

FREDERICTON, NB, Sept. 14, 2023 /PRNewswire/ - SmartSkin Technologies is proud to announce that Martin Van Trieste, former Chief Quality Officer at Amgen, CEO of Civica Rx and founder of Rx-360, will succeed Gerry Pond as Chair of the Board of Directors.

Key Points: 
  • FREDERICTON, NB, Sept. 14, 2023 /PRNewswire/ - SmartSkin Technologies is proud to announce that Martin Van Trieste, former Chief Quality Officer at Amgen, CEO of Civica Rx and founder of Rx-360, will succeed Gerry Pond as Chair of the Board of Directors.
  • "Martin likes to say that quality comes free when you design it into the process," said Evan Justason, CEO of SmartSkin.
  • A single batch rejection can result in millions of dollars in losses," said Van Trieste.
  • "SmartSkin not only allows manufacturers to pinpoint problem areas and address issues on the spot, but it enables proactive risk management.

Veeva Vault LIMS to Support Civica Rx Quality Control

Retrieved on: 
Tuesday, August 22, 2023
Civica Rx, Quality control, Civica, LIMS, Veeva Systems, QC, Patient, NYSE, Locksmithing, Entertainment

PLEASANTON, Calif., Aug. 22, 2023 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Civica Rx (Civica) has adopted Veeva Vault LIMS to optimize quality control. Vault LIMS builds on Civica's success with Veeva Vault QMS, Veeva Vault QualityDocs, and Veeva Vault Training and establishes a foundation for unified lab and quality processes to support a new manufacturing facility.

Key Points: 
  • PLEASANTON, Calif., Aug. 22, 2023 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Civica Rx (Civica) has adopted Veeva Vault LIMS to optimize quality control.
  • Vault LIMS builds on Civica's success with Veeva Vault QMS , Veeva Vault QualityDocs , and Veeva Vault Training and establishes a foundation for unified lab and quality processes to support a new manufacturing facility.
  • Within Vault LIMS, lab professionals will be able to reference relevant methods and specifications stored in Vault QualityDocs and surface relevant quality events from Vault QMS during final QC review.
  • "Veeva Vault LIMS will help Civica create an advanced quality control lab with a simple and efficient user experience," said Jason Boyd, senior director, Veeva Vault LIMS.

Veeva Vault LIMS to Support Civica Rx Quality Control

Retrieved on: 
Tuesday, August 22, 2023
Civica Rx, Quality control, Civica, LIMS, Veeva Systems, QC, Patient, NYSE, Locksmithing

BARCELONA, Spain, Aug. 22, 2023 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Civica Rx (Civica) has adopted Veeva Vault LIMS to optimize quality control. Vault LIMS builds on Civica's success with Veeva Vault QMS, Veeva Vault QualityDocs, and Veeva Vault Training and establishes a foundation for unified lab and quality processes to support a new manufacturing facility.

Key Points: 
  • BARCELONA, Spain, Aug. 22, 2023 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Civica Rx (Civica) has adopted Veeva Vault LIMS to optimize quality control.
  • Vault LIMS builds on Civica's success with Veeva Vault QMS , Veeva Vault QualityDocs , and Veeva Vault Training and establishes a foundation for unified lab and quality processes to support a new manufacturing facility.
  • Within Vault LIMS, lab professionals will be able to reference relevant methods and specifications stored in Vault QualityDocs and surface relevant quality events from Vault QMS during final QC review.
  • "Veeva Vault LIMS will help Civica create an advanced quality control lab with a simple and efficient user experience," said Jason Boyd, senior director, Veeva Vault LIMS.

Global Generic Drugs Market Report 2022: Aging Population and Increasing Incidences of Chronic Diseases Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Friday, September 9, 2022
General Health, Pharmaceutical, Health, COVID-19, Conditional sentence, Safety, Research, Ageing, Lists of countries and territories, Patent, Hospital, Organization, Medicine, FDA, CAGR, Population, Civica Rx, USFDA, Pharmaceutical industry, Generic drug, Growth

The "Generic Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Generic Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.
  • The global generic drugs market reached a value of US$ 320 Billion in 2021.
  • Due to an aging population and increasing incidences of chronic diseases, governments of developed countries have been making efforts to reduce healthcare costs by promoting the production of generics.
  • The publisher provides an analysis of the key trends in each sub-segment of the global generic drugs market, along with forecasts at the global and country level from 2022-2027.

Civica Selects Profil as Clinical Trial Partner for Affordable Insulin Initiative

Retrieved on: 
Thursday, June 2, 2022
Health, FDA, Medical Devices, Diabetes, Clinical Trials, Research, Science, Insulin analog, Company, Research, Knowledge, Prediabetes, Pharmacokinetics, Pharmacology, Physician, FDA, Insulin, Biosimilar, Diabetes, Obesity, Clinical trial, Insulin lispro, Drug development, Civica Rx, AP, Safety, Insulin aspart, Pancreas, Pharmaceutical industry, Insulin glargine, Civica, Profil

Civica, Inc. (Civica, Civica Rx) today announced the selection of Profil, Neuss, Germany, as its clinical trial partner to support the development of its affordable insulins.

Key Points: 
  • Civica, Inc. (Civica, Civica Rx) today announced the selection of Profil, Neuss, Germany, as its clinical trial partner to support the development of its affordable insulins.
  • Profil has conducted over 30 biosimilar insulin trials and is the leading clinical research organization for studies related to diabetes.
  • With its extensive experience and quality track record, Profil is the ideal clinical trial partner for Civica.
  • More information on Civica and its affordable insulin initiative, including commentary from partners and a fact sheet, can be found at https://civicainsulin.org .

Intermountain Healthcare and General Catalyst to Collaborate on Innovation

Retrieved on: 
Monday, May 9, 2022
Olive, Privacy, Lake City, Catalysis, Population, Health, GLOBE, Physician, Time, General officer, Intermountain Healthcare, Hospital, MD, University of Kansas Health System St. Francis Campus, Movement, Civica Rx, General Catalyst, Population health, Solution, HubSpot, Growth, Digital, Medicine, Illumio, Intermountain, Lemonade, Transcare EMS, Cadence, Gusto

The collaboration will involve jointly exploring opportunities within the Intermountain system and within healthcare in general to accelerate the shift to value-based care through digital and other solutions offered by companies in the Health Assurance Network.

Key Points: 
  • The collaboration will involve jointly exploring opportunities within the Intermountain system and within healthcare in general to accelerate the shift to value-based care through digital and other solutions offered by companies in the Health Assurance Network.
  • This collaboration between Intermountain and General Catalyst can help turbocharge the movement towards population health and value-based care by connecting us with a network of innovators outside the traditional healthcare space.
  • Marc and the Intermountain team are on the forefront of making value-based care a reality, said Hemant Taneja, Managing Partner at General Catalyst.
  • General Catalyst works closely with the companies building the network of health assurance including Commure, Tendo, Transcarent and Olive.

Alcami Partners with Civica Rx in Multi-Year Agreement

Retrieved on: 
Tuesday, May 3, 2022
Laboratory, Madison Dearborn Partners, CGMP, Partnership, Environmental monitoring, CDMO, Excipient, Civica Rx, View, Civica, CEO, Microbiology, Multimedia, Pharmaceutical industry, Management

With the execution of this agreement, Alcami will provide analytical support for products to be manufactured at Civica's 140,000 square-foot sterile injectable manufacturing facility in Petersburg, Virginia.

Key Points: 
  • With the execution of this agreement, Alcami will provide analytical support for products to be manufactured at Civica's 140,000 square-foot sterile injectable manufacturing facility in Petersburg, Virginia.
  • "We are proud to support Civica and the important work they are doing to ensure the supply of high-quality generic medicines in the United States," said Timothy Compton, Chief Business Officer of Alcami.
  • "Alcami will provide testing services for products developed and manufactured for and at our Civica Petersburg manufacturing facility," said Martin VanTrieste, President and CEO of Civica Rx.
  • Alcami's private equity ownership includes Madison Dearborn Partners and Ampersand Capital Partners.

Global Generic Drugs Market Report 2022: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2017-2027 - ResearchAndMarkets.com

Retrieved on: 
Monday, March 28, 2022
Health, Pharmaceutical, CAGR, Organization, Population, Conditional sentence, Civica Rx, Patent, Research, Government, Hospital, United States Secretary of Labor, Medicine, USFDA, Safety, Ageing, COVID-19, Lists of countries and territories, Nature, FDA, OTC, Privacy and the US government, Fine chemical, Pharmaceutical industry, Growth

The "Generic Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Generic Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.
  • The global generic drugs market reached a value of US$ 320 Billion in 2021.
  • A generic drug is a medicine that contains the same active ingredient and has an equivalent therapeutic effect as the branded drug.
  • The company is producing 14 short-supply, FDA-approved drugs that have been available in the market since the beginning of 2019.

RxS LLC expands into patient care with PatientCentral offering

Retrieved on: 
Friday, March 11, 2022
Empathy, DTP, Civica Rx, Nursing, HUB, Pharmacy, Caregiver, Patient, Compliance, Health, Pharmacist, Technology, Healthcare

PatientCentral is a technology-enabled service that provides brands and manufacturers a single point of contact with their patients and patient caregivers.

Key Points: 
  • PatientCentral is a technology-enabled service that provides brands and manufacturers a single point of contact with their patients and patient caregivers.
  • RxS LLC, is an international, multi-channel sample management solution provider to the life science and pharmaceutical industries.
  • According to RxS Principal and Managing Director Mark Jara, "The chief objective of PatientCentral is to enable brands to positively affect patient journeys.
  • To learn more about the RxS patient HUB, PatientCentral, users are encouraged to visit: PatientCentral , the newest member of the RxS family of services (rxsinfo.com) .